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Abstract
Stress has been shown to facilitate ethanol withdrawal-induced anxiety. Defining neurobiological
mechanisms through which stress has such actions is important given the associated risk of
relapse. While CRF has long been implicated in the action of stress, current results show that
stress elevates the cytokine TNFα in the rat brain and thereby implicates cytokines in stress
effects. In support of this view, prior TNFα microinjection into the central amygdala (CeA) of rats
facilitated ethanol withdrawal-induced anxiety—a response that could not be attributed to an
increase in plasma corticosterone. To test for a possible interaction between cytokines and CRF, a
CRF1-receptor antagonist (SSR125543) administered prior to the repeated administration of TNFα
or MCP-1/CCL2 reduced the magnitude of the withdrawal-induced anxiety. This finding provided
evidence for cytokine action being dependent upon CRF. Additionally, the sensitizing effect of
stress on withdrawal-induced anxiety was reduced by treating the repeated stress exposure prior to
ethanol with the MEK inhibitor SL327. Consistent with cytokines having a neuromediator
function distinct from a neuroimmune action, TNFα increased firing rate and GABA release from
CeA neurons. Thus, an interaction of glial and neuronal function is proposed to contribute to the
interaction of stress and chronic ethanol. Interrupting this potential glial-neuronal interaction could
provide a novel means by which to alter the development of emotional states induced by stress
that predict relapse in the alcoholic.
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1. Introduction
Stress has long been thought to be a significant factor in the etiology of alcoholism (e.g.,
Breese et al., 2005a,b, 2011; Koob, 2009; Pohorecky, 1981; 1991; Sinha and Li, 2007). For
example, clinical laboratory studies demonstrate that abstinent alcoholics respond with
enhanced craving for alcohol (ethanol) when they are exposed to stress-related or ethanol
cue-related images (Fox et al., 2007; Sinha and Li, 2007; Sinha et al., 2009). Further,
anxiety and stress disorders are considerably over-represented in alcoholics, and self-
medication of these and related negative emotional states with ethanol remains a conceptual
and experimental focus of both basic and clinical research (e.g., Breese et al., 2005a,b;
Brady and Lydiard, 1993; Regier et al., 1990; Zhang et al., 2007). Acute and persistent
vulnerability to stress both during acute withdrawal from alcohol and beyond the acute
withdrawal period (i.e., during extended abstinence) may play an important role in
perpetuating maladaptive drinking behavior. Results from rodent models of chronic ethanol
exposure, particularly cyclic patterns of ethanol exposure and withdrawal, support the idea
that progressively worsening profiles of withdrawal-like states arise and may persist over
time to render subjects vulnerable to future environmental stressors and challenges (Breese
et al., 2005b; Overstreet et al., 2002; Valdez et al., 2002). A number of neurobiological
substrates, including those associated with GABA, serotonin, norepinephrine, and
corticotrophin releasing factor (CRF) have been implicated in this vulnerability (e.g., Breese
et al., 2005b; Koob, 2010; Smith and Aston-Jones, 2008). CRF, in particular, appears to be
integral in acute and persistent vulnerability to stress in alcohol dependence (Huang et al.,
2010; Koob, 2010; Lowery and Thiele, 2010). Recent data also implicate the cytokine/
chemokine systems in CNS sensitization (e.g., Kawasaki et al., 2008) and in the etiology of
chronic ethanol-related phenotypes (Breese et al., 2008; Qin et al., 2008). For example, prior
administration of LPS or cytokines/chemokines accelerates the development of anxiety-like
behavior in animals subsequently exposed to ethanol and withdrawal (Breese et al., 2008).
Further, profound enhancement of LPS effects on brain cytokines has been observed in
rodents pretreated with chronic ethanol (Qin et al., 2008). Elevated levels of the chemokine
monocyte chemotractant protein-1 (MCP-1/CCL2) have been found in several regions of the
human post-mortem alcoholic brain including the amygdala (He and Crews, 2008).
Some evidence demonstrates comparable effects of CRF and cytokines on alcohol-related
maladaptations and is consistent with a possible interactive role of cytokines and CRF in
ethanol withdrawal phenotypes including stress vulnerability indexed by anxiety-like
behavior (Breese et al., 2004; 2005; 2008; Huang et al., 2010; Overstreet et al., 2004).
Further, evidence suggests that the amygdala plays a key role in these behaviors (e.g.,
Huang et al., 2010; Knapp et al., 2007). The experiments described herein were designed to
explore the hypothesis that CRF and cytokines may work together to worsen ethanol
withdrawal phenotypes through actions in specific brain regions including the amygdala. In
a series of experiments, the effects of stress on brain cytokines and the effects of cytokines
on neuronal physiology in the amygdala were investigated, and potential interactions of CRF
and cytokines on ethanol withdrawal-related behavior attributable to functions of the
amygdala were assessed.
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Six experiments were conducted. Experiment 1 examined the brain’s TNFα response to
acute restraint stress relative to unstressed controls. Experiment 2 challenged the amygdala
with the cytokine TNFα or vehicle prior to 5 days of 7% ethanol diet (ED) or control diet
(CD) exposure to determine whether future ethanol withdrawal anxiety responses (reduced
social interaction behavior) at 5 hrs into withdrawal would be magnified. Experiment 3
examined the consequence of intra-amygdala TNFα or vehicle injections or stress on plasma
corticosterone levels. Experiment 4 employed a CRF-1 receptor antagonist administered
peripherally in an attempt to block effects of intracerebroventricular (ICV) cytokine/
chemokine administration (MCP-1 or TNFα) enhancement of future withdrawal anxiety 24
hours after cessation of 4.5% ED drinking. Experiment 5 examined a downstream receptor
effector mechanism (pERK activity) while Experiment 6 assessed the electrophysiological
responses of amygdala neurons to TNFα. Additional details of the experimental protocols
for Experiments 1–5 are depicted in Figure 1.
2.2. Animals and Housing
Adult male Sprague-Dawley rats (180–220 g at the start of experiments, Charles River,
Raleigh, NC, or Harlan, Dublin, VA) were used for behavioral studies while 13–20 day old
male Sprague-Dawley rats bred in house from Charles River stock parents were used for
electrophysiology. Adult rats were group housed upon arrival for up to a week prior to
surgeries or entering a study. Rats were then isolate housed for the remainder of the
experiments. Animal facility temperatures and humidity were maintained at 70–74 °F and
40–60% humidity with lights on at 07:00 and off at 19:00. All adult animals received
RMH3000 rat chow (TestDiets, Richmond, IN) until they were switched to liquid diets. All
studies using animals were approved by the Institutional Animal Care and Use Committee at
the University of North Carolina, Chapel Hill.
2.3. Liquid Diets
Ethanol-containing or control diets were employed as previously described (e.g., Knapp et
al., 2007; Overstreet et al., 2002; Wills et al., 2008). Briefly, rats were exposed to either CD
or a 4.5% or 7% ED liquid diet in a modified pair-feeding fashion for the periods described
in the relevant experiments below. The diets were nutritionally complete and calorically
balanced with appropriate concentrations of dextrose versus ethanol. Rats first received ICV
or amygdala cannuli implants via stereotaxic surgery as applicable 3 days prior to receiving
CD initially to adapt to the novel food source. Rats then received drug injections and then
ethanol-containing diets as described below. Ethanol withdrawal was then initiated by
switching rats from ED to CD on the morning of behavioral test (which occurred between 5
and 24 hours post-withdrawal). The protocol for employing the diets in the context of the
experiments is shown in Figure 1.
2.4. Surgeries
Rats that had cannuli implanted were anesthetized with isoflurane, the skulls exposed, and
holes drilled for a 26 gauge stainless steel cannula implanted into the brain to a point
directly above the target region (the lateral ventricle or the central nucleus of the
amygdala---CeA). Two additional holes for machine screws facilitated securing the cannuli
with dental cement. The coordinates for placement of the ICV cannula tip were (in mm)
−0.8 AP, −1.6ML, and −2DV based on the atlas of Paxinos and Watson (2005). For the
central amygdala injections, the cannuli coordinates were 2.3, − 4.5, and −5.5. The
placements were such that during the subsequent drug injections, the injector needle
Knapp et al. Page 3













(described below) protruded 2.5 mm deeper (DV) than the cannula tip for the ICV and
central amygdala injections. A 32-gauge stainless steel wire plug kept the cannuli closed
when not in use for injections. Animals were allowed to recover at least 3 days prior to
proceeding to other treatments.
2.5. Drugs/chemicals
TNFα was recombinant rat TNFα/TNFSF1A (R & D Systems, Minneapolis, MN; 10 or 100
ng/0.5 µl in each amygdala or 100 ng/5 µl ICV as per Breese et al., 2008), and MCP-1 was
carrier-free recombinant rat (Leinco Technologies, St. Louis, MO; 100 ng/0.5 µl, as per
Breese et al., 2008; Plata-Salaman et al., 1994;1996). Cytokines were prepared in artificial
cerebrospinal fluid (aCSF) comprised of pyrogen-free sterile water containing 217 mM
NaCl, 3 mM KCl, 1 mM CaCl2 2H20, 1mM MgCl2·6H20, 0.8 mM Na2HPO4 7H20, and 0.2
mM NaH2PO4·H20. ICV or amygdala injections were made over 1 minute via a 32- gauge
stainless steel injector guided to the site of interest via the indwelling cannula. Injectors were
left in place for 1 minute to accommodate drug dispersal at the injection site. The CRF-1
receptor antagonist SSR125543, a gift of Sanofi-Aventis (Montpellier, France), was
prepared in saline with 2% Tween-80 at 5 mg/ml and administered IP (10 mg/kg). Vehicles
for all control injections were identical to those used to prepare the respective drugs.
MCP-1, TNFα, and SSR125543 were made and used immediately or stored in ready-to-use
aliquots for up to 24 hours at 4°C or up to 3 months at −80°C. The MEK inhibitor SL327
(Ascent Scientific, Princeton, NJ) was prepared at 1 µg/5 µl in aCSF containing 1% DMSO
and injected ICV. Finally, for electrophysiology, buffers/reagents are described in the
relevant section below.
2.6 Stress
Some rats were stressed twice for 60 minutes in plastic decapicone restrainers then returned
to home cages for 4.5 hours (Experiment 1) prior to sacrifice (5.5 hours after the start of
stress). A second set of animals (Experiment 3) was stressed for 30 minutes and processed as
described below for blood collection. Finally, others were injected with SL327 or its vehicle
30 min prior to two 60-min stress sessions 7 days apart. These rats then continued in the
protocol described below (Experiment 6).
2.7. Social Interaction Test
The social interaction (SI) test is a validated index of anxiety-like states in rats (File and
Hyde, 1978; File and Seth, 2003), and this test has been adapted for general use in our
laboratory (Breese et al., 2004, 2005b; Knapp et al., 2005; Overstreet et al., 2002, 2003,
2004). In the 5-minute SI test, rats of approximately similar sizes were placed into a 60 × 60
cm square black Plexiglas open field with 15 × 15 cm squares marked on a clear plexiglas
floor under low lighting conditions (30 lx). The amount of aggregate time each rat was
engaged in social behavior (conspecific grooming, sniffing, following, crawling over/under
its partner) was recorded by a blinded observer. An elevated anxiety-like response was
inferred from reduced social interaction behavior. Line crosses were also recorded as a
measure of locomotor activity.
2.8. Blood and Brain Tissue Collection
At 45 min after intra-amygdala administration of TNFα (Experiment 3) and 15 minutes after
the termination of the stress, some rats were sacrificed for trunk blood for
radioimmunoassay of corticosterone. Blood was heparinized, kept on ice, then centrifuged at
2600 g for 10 minutes and the supernatants (plasma) collected and stored at −80°C until
assayed. Brain tissue for TNFα measures were obtained following rapid decapitation,
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extraction and freezing of brains in isoflurane at −25 °C. Sagittal cuts at the midline of each
brain provided half-brains (hemispheres) of each rat that were processed for TNFα.
2.9. Corticosterone and TNFα Measures
Plasma corticosterone was assayed as per the manufacturer’s instructions using a 125I Rat
and Mouse kit supplied by MP Biomedicals (Orangeburg, NY). Radioactivity was assessed
relative to standard curves with an LKB Wallac 1282 Compugamma counter (Akribis
Metrology, Worcestershire, UK). For TNFα measures, brain tissue was homogenized for 45
seconds in 10 ml of homogenization buffer (20 mM TRIS, 0.25 M Sucrose, 0.2 mM EDTA,
10 mM EGTA, 1% Triton X-100) including a protease inhibitor (Roche, Cat# 11 836 153
001). Homogenates were centrifuged at 12,000 g for 30 minutes at 4°C and the resultant
supernatant was aliquoted and stored at −80°C until analysis. ELISA kits were purchased to
analyze levels of TNFα (RayBiotech, Inc., Norcross, GA). All ELISA experiments were
performed according to manufacturer’s instructions. Standard curves with levels from 0–
20,000 pg/ml were created for each cytokine using the recombinant rat cytokine provided in
each kit. In addition, a BCA Protein analysis (Pierce Biotechnology, Inc., Rockford, IL) was
performed to determine total protein levels for all samples. All data were collected using a
Spectramax Plus384 microplate spectrophotometer (Molecular Devices, Inc., Sunnyvale,
CA). Absorbance was at 450 nM for all cytokine ELISA kits, and was 562 nM for the BCA
protein analysis. Resulting data were the normalized to total protein levels.
2.10. Electrophysiology: Preparation of brain slices
Sprague-Dawley rats, 13–20 days old, were anesthetized by i.p. injection of 75% urethane
and decapitated. The brains were rapidly removed and placed in ice-cold aCSF of the
following composition (in mM): NaCl 124, KCl 3.25, KH2PO4 1.25, CaCl2 2, NaHCO3 20,
MgSO4 2, and glucose 10. Coronal sections through the CeA were cut with a vibrating tissue
slicer (Vibratome, Series 1000). The slices were stored in a beaker containing aCSF gassed
with 95% O2/5% CO2. The slices were equilibrated at least 1 hour at room temperature
before starting experiments. For electrophysiological recording, the brain slice was placed at
the bottom of a chamber and superfused with aCSF gassed with 95% O2/5% CO2 at a flow
rate of 0.5–1 ml/min and the chamber maintained at room temperature (21–24 °C). The cells
in slices were visualized under IR illumination with differential interference contrast optics
and a water-immersion lens (40X/0.80 W), with the image shown in a monitor via a video
camera.
2.11. Electrophysiological Recording
Electrophysiological studies were performed under either voltage-clamp at −60 mV in the
whole-cell configuration for mIPSCs or in loose-patch configuration at 0 mV for action
potential recording using an Axopatch-1D amplifier (Axon Instruments/Molecular Devices,
Sunnyvale, CA). Recording pipettes were fabricated from N 51A capillary glass
(Drummond Scientific, Broomall, PA). The internal solution for voltage-clamp recording
included (in mM) KCl 150, MgCl2 3.1, HEPES 15, K-ATP 2, EGTA 5, phosphocreatine 15,
and 50 U/ml creatine phosphokinase, adjusted to pH 7.4 with KOH and to an osmolality of
310 mosmoles/L (adjusted with sucrose). For action potential recording the 15 mM
phosphocreatine and 50 U/ml creatine were not included in the internal solution. The KCl
was included in the solution during action potential recording to maintain baseline cell
firing. For voltage-clamp recording, seals were formed on the neurons with electrodes
having a tip resistance of 2–4 MΩ. Data were displayed on an oscilloscope, digitized at 2
kHz, and stored on a personal computer. Recordings were performed at room temperature in
a bath where the neurons were superfused at 0.5–1 ml/min. TNFα was dissolved in aCSF
and applied by a drug perfusion pencil with a diameter of 250 µm for a 2 min interval. The
mIPSC rate or the rate of action potentials during the last 30 sec period of that interval was
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compared to rate in the 30 sec period preceding the cytokine application. In control
recordings, the TNFα was replaced with aCSF. Control (aCSF) and TNFα-containing aCSF
solutions were delivered through Teflon tubing connected with the multi-barrel perfusion
pencil positioned 150–250 m from the cells tested. Data were collected with Clampex 8.1
software (Axon Instruments) and prepared as mean ± SEM. Action potential/firing rates or
mIPSCs were computed using MiniAnalysis (Synaptosoft; Decatur, GA).
2.12. Data Analysis
For social interaction and locomotor scores, plasma corticosterone, and brain TNFα, t-tests
or 1-way or 2-way ANOVA were used for 2-group versus multiple-group analyses. Fisher’s
PLSD tests were used for comparisons of individual pairs of groups within an experiment.
For electrophysiological data, pre- and post-TNFα action potentials/firing rates and mini-
inhibitory post-synaptic currents were averaged for a baseline then related to recordings
made during the presence of TNFα by computing a change from this baseline. Similarly
calculated means derived from vehicle/buffer-only exposed cells were then compared with
the data from the TNFα exposed cells with t-tests. Group differences deemed significant at
p<0.05.
3. Results
3.1. Experiment 1. Effect of Restraint Stress on Brain TNFα
This experiment focused on collecting data on brain TNFα following the restraint utilized in
previous experiments to sensitize ethanol withdrawal anxiety. Figure 2 depicts an
approximate doubling of brain TNFα 5.5 hours after the start of 60 minutes of restraint stress
relative to unstressed control rats, t(6) = 3.12, p< 0.05.
3.2. Experiment 2. Effect of TNFα Microinjection into the Central Amygdala on Facilitation
of Ethanol Withdrawal Anxiety
This experiment was conducted to assess the consequences of exogenously administered
TNFα into the amygdala on behavioral consequences of subsequent chronic ethanol and
withdrawal. As shown in Figure 3, there was a main effect of the ethanol exposure, F(1,34),
= 42.0, p<0.0001 and an interaction of ethanol exposure and drug treatment, F(1,34) = 10.1,
p<0.01. Posthoc tests revealed that by itself, TNFα administered to controls exerted no
significant effect on future anxiety (p >0.05), nor did vehicle injections induce an anxiety
response different than control animals that had never had stereotaxic surgery and
microinjections (e.g., Knapp et al., 2005). The 7% chronic ED alone modestly but
significantly reduced social interaction by 27% (p<0.05 versus vehicle treated rats). In
contrast, the combination of chronic ethanol and TNFα markedly reduced social interaction
by 66% (p<0.05 versus vehicle treated rats) (Figure 3). Body weights, ethanol intakes, and
locomotor behavior are shown in Table 1.
3.3. Experiment 3. Effect of TNFα microinjection into the Amygdala on Plasma
Corticosterone
To demonstrate the potential role of corticosterone in the effects of TNFα, this experiment
assessed plasma corticosterone levels following stress or intra-amygdala TNFα
administration. Overall, treatment effects were significant, F(2,15) = 27.4, p<0.0001. Figure
4 illustrates that plasma corticosterone was not altered by a TNFα dose 10 times that utilized
for Figure 3 (p>0.05). Restraint stress produced the expected increase in corticosterone
(p<0.05 versus either TNFα- or aCSF-treated controls).
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3.4. Experiment 4. Effect of a CRF1 Receptor Antagonist on Cytokine Facilitation of
Ethanol Withdrawal Anxiety
Previous work had suggested that the action of cytokines may depend upon CRF (Borsody
et al., 2002; del Cerro and Borrrell, 1990; Kohman et al., 2007). To probe the potential
interaction of CRF and cytokine systems in ethanol withdrawal-induced anxiety, this
experiment included injections of CRF-1 receptor antagonist prior to the repeated weekly
TNFα treatment in an attempt to block cytokine facilitation of ethanol withdrawal anxiety.
MCP-1 was also examined to confirm an earlier finding (Breese et al., 2008) and to extend
the examination of CRF receptor antagonism to this chemokine. Overall, there was a
significant treatment effect, F(6,52) = 8.30, p< 0.0001. Figure 5 shows the effects of a single
5-day cycle of chronic ethanol alone (4.5%ED) versus the combination of TNFα or MCP-1.
Both cytokines dramatically increased future ethanol withdrawal-induced anxiety-like
behavior (p<0.05 versus controls). The CRF-1R antagonist SSR125543 administered prior
to each of the two cytokine treatments mitigated this effect. Responding in these animals
was significantly higher than in animals treated only with the cytokines and ethanol (p<0.05)
and was not different from animals that received neither of these treatments (p>0.05).
3.5. Experiment 5. Demonstration that a MEK Inhibitor Blocks Stress Facilitation of Ethanol
Withdrawal-Induced Anxiety
This experiment attempted an initial probe of the potential role of the MEK pathway in the
effects of stress in an ethanol withdrawal-induced anxiety model. For this experiment the
MEK inhibitor SL327 was injected intraventricularly prior to each stress applied before the
5-day regimen of chronic ethanol. As shown in Figure 6, a main effect of ED/stress
treatment was found, F(1,24 = 4.97, p<0.05. While there was no effect of drug treatment
alone (p>0.05), an interaction of ED/Stress treatment by drug treatment was found, F(1,24)
= 12.02, p<0.01. Posthoc tests showed significant differences between the ED/Stress treated
group and all other groups (p<0.05).
3.6. Experiment 6: Demonstration of a TNFα Increase in Firing Rate and Release of GABA
from CeA Neurons
To assess the potential direct actions of cytokines on neuronal activity in a brain region
relevant to chronic ethanol withdrawal anxiety (Huang et al., 2010), this experiment
examined electrophysiological effects of TNFα on neurons in the central amygdala. Figure 7
shows that a stable pre-TNFα firing rate of an amygdala neuron was significantly increased
during the acute 2-minute application of TNFα. The percent increase in TNFα-driven firing
from the average of the pre- and post-TNFα firing rate was found to be significant with a t-
test (t(21) = 2.18, p<0.05). Figure 7 also shows additional functional neuronal consequences
of TNFα in a separate set of amygdala neurons. TNFα elevated presynaptically-mediated
GABA release (mIPSCs) (t(22) = 2.22, p<0.05 relative to non-TNFα-exposed cells).
4. Discussion
The results of these experiments add to a growing body of literature showing that stress can
initiate and maintain alcohol abuse as well as a variety of psychiatric disorders. Previous
work demonstrated that restraint stress prior to chronic ethanol facilitated ethanol
withdrawal-induced anxiety-like behavior (Breese et al., 2004). This stress was shown to
elevate TNFα in brain, a finding consistent with previous studies showing that stress
elevates brain cytokines (Deak et al., 2005; Minami et al., 1991; Nguyen et al., 1998;
O’Connor et al., 2003; Shintani et al., 1995; Shizuya et al., 1997; Suzuki et al.,1997).
Subsequent studies may benefit from defining potential shifts in TNFα dose response curves
in alcohol exposed versus controls in brain regions thought to be relevant to this anxiety-like
response. Likewise, defining the effect of stress on cytokine levels at additional time points,
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in more discrete brain regions, or in the presence of cytokine inhibition (e.g. antagonists)
could provide further functional relevance for the effect of stress to increase TNFα or other
cytokines in brain.
The mechanism(s) by which stress and cytokines influence ethanol action are not well
understood. When chronic ethanol in adult rats is limited to 5 days, anxiety during
withdrawal were minimal or absent (Breese et al., 2008; Huang et al., 2010; Overstreet et al.,
2002; 2003). However, when stress, CRF, or MCP-1 or TNFα injections were applied at
weekly intervals prior to this ethanol regimen (Breese et al., 2008; Huang et al., 2010;
Overstreet et al., 2002; 2003), social interaction deficits were unmasked during withdrawal.
These findings suggest an adaptation to these various challenges sensitizes ethanol
withdrawal anxiety. Moreover, earlier work indicated that selected brain sites supported the
facilitation of ethanol withdrawal anxiety (e.g., Huang et al., 2010; Knapp et al., 2007;
Overstreet et al., 2006). Based upon the demonstration that cytokines administered ICV
prior to chronic ethanol sensitize ethanol withdrawal anxiety (Breese et al., 2008),
microinjection of TNFα into the amygdala was examined and shown to elevate anxiety-like
behavior during ethanol withdrawal. This finding underscores the potential role of this brain
site in the cumulative adaptation induced by TNFα that modifies the effect of chronic
ethanol. Future experiments are planned to determine whether other cytokines will act in the
amygdala and to define the minimal dose that affects withdrawal responses.
The results of the TNFα microinjections suggest that an extra-hypothalamic action of
cytokines contributes to chronic ethanol effects on behavior. While administration of
corticosterone to animals in an earlier study did not reproduce stress effects on ethanol
withdrawal anxiety (Breese et al., 2004), it had not been tested whether this sensitizing
effect of TNFα could relate to the HPA axis activation (Turnbull and Rivier, 1999). Thus,
the present investigation sought to explore potential role of the HPA axis in the action of
TNFα by administering cytokine directly into the amygdala. This treatment did not alter
plasma corticosterone (Figure 4). Thus, while enhanced cytokine function can elevate HPA
axis activity (Pérez-Nievas et al., 2010; Turnbull and Rivier, 1999) and increase withdrawal
anxiety (Breese et al., 2008; present data), it would be difficult to argue that the response to
TNFα was mediated by an activated HPA axis.
One caveat in the interpretation of the anxiety phenotype in these studies is the fact that 7%
ED (approx 10 g/kg/day over 5 days) was used in the experiment with TNFα microinjection
to elicit a degree of withdrawal upon which TNFα treatment could be superimposed. This
treatment reduced SI behavior as well as locomotor responses such that the withdrawal
response was not necessarily restricted to an anxiety-like state. While locomotor behavior
was reduced in both ethanol-treated groups in the TNFα experiment, the most dramatic
anxiety response was found in the group treated with TNFα with limited anxiety effects on
the group treated with ethanol alone. Thus, the anxiety effect and the locomotor change
appear to have varied independently of each other as previously reported (Overstreet et al.,
2002), and the anxiety measure does not appear to depend upon altered locomotion.
Nevertheless, subsequent ethanol-related experiments incorporated systematic modifications
in the ethanol concentration and timing of behavioral measures to optimize isolation of the
anxiety-like response. In this regard, reduced locomotion observed in the TNFα experiment
with the 7% ED is less likely to be seen with lower concentrations of ED (e.g., Knapp et al.,
2007; Overstreet et al., 2002; Wills et al., 2009). That is, this effect is either not observed in
these earlier experiments in which TNFα was administered ICV or is at best limited when in
groups receive stress given prior to ethanol exposure (e.g., Table 1).
This stress-facilitated effect on withdrawal anxiety is sensitive to pharmacological
manipulation (Breese et al., 2004). Among the drugs that prevented this sensitization of
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withdrawal anxiety was a CRF1R antagonist. The CRF1R antagonist SSR125543 was
administered prior to ICV administration of TNFα and MCP-1 that were given prior to the
chronic ethanol exposure to consequences on ethanol withdrawal anxiety. The ICV
cytokines administered twice prior to the subthreshold chronic ethanol experience produce
social interaction deficits similar to those previously reported (Breese et al., 2008). The
CRF1R antagonist blocked the cytokine-induced sensitization of withdrawal anxiety. Given
that the CRF1R antagonist prevents sensitization by stress as well as by CRF (Breese et al.,
2004; Overstreet et al., 2004), our new results are consistent with CRF impacting cytokines
(Borsody et al., 2002; del Cerro and Borrrell, 1990; Kohman et al., 2007). A schematic
representation of cytokine/CRF interactions that may be involved in this response is
depicted in Figure 8. This potential involvement of CRF in microglia actions is based in part
on upon Wang et al. (2002, 2003) who demonstrated that CRF activation of CRF-1Rs on
microglia facilitate release of cytokines. These and other results suggest the possibility that
stress-induced release of CRF can release cytokines (Wang et al., 2002, 2003), which in turn
facilitate further CRF release (del Cerro and Borrell, 1990). The results described herein
extend these observations by implicating an interaction of cytokines and CRF in stress
associated with alcohol withdrawal and by implicating CRF in sensitized withdrawal anxiety
following repeated cytokine exposures (Figure 8). Overall, these experiments are consistent
with a growing body of evidence implicating CRF in stress and chronic ethanol effects that
influence emotional behavior and ethanol consumption (Breese et al., 2010; Heilig and
Koob, 2007 for reviews).
CRF, as well as cytokines and LPS, have been shown to engage pERK (Hauger et al., 2009;
Jara et al., 2007; Munhoz et al., 2010). The latter findings and the results herein suggest that
CRF-1R and/or cytokine receptors engage signaling events that impact on adaptive
responses that in turn may render animals more prone to emotional responding and more
vulnerable to future challenges to stress. Therefore, it was reasoned that if cytokines, CRF,
and stress influence adaptation to chronic ethanol, then perhaps this 2nd messenger pathway
is involved and that inhibition of MEK would prevent the stress-induced sensitization of the
ethanol withdrawal anxiety. Results showed that SL327 administered prior to stress
inhibited development of anxiety arising from ethanol withdrawal. While this experiment
did not directly test whether the behavioral effects of manipulating the MEK pathway are
unique to glia or to neural function, it was also shown that SL327 had no actions in controls.
Additional work to assess pERK and related kinase signaling pathways in this model are
warranted to further define the generalizability of the findings and the mechanisms and cell
types involved in the maladaptive responses generated in the model.
Since cytokines must act on their individual receptors to influence neural function, evidence
was sought for this action by determining if the actions of TNFα in the amygdala could be
associated with direct effects of TNFα on neural function. Figure 7 shows that TNFα
increased firing rates and facilitated GABA release in the CeA, an area of the brain long
known to regulate emotional behavior and ethanol withdrawal behaviors (Knapp et al.,
2007; Koob, 2009). The results are consistent with the idea that direct actions of cytokines
on neurons may mediate some of the effects of TNFα seen in our studies. This finding is
consistent with a neuromodulatory action of cytokines distinct from their neuroimmune
action (e.g., Adler et al., 2006; Bauer et al., 2007; Rostène et al., 2007; Shi et al., 2010). As
neuromodulators, cytokines may be integral pathophysiologic contributors to drug abuse and
other neurobehavioral disorders (Anisman and Merali, 2003; Dunn et al., 2005; Hayley et
al., 2005; Pucak and Kaplin, 2005; Raison et al., 2006; Uddin et al., 2010). Because these
physiological effects were recorded in neurons of young rats, they may not perfectly
represent effects in adults. However, this demonstration of neural action is consistent with
the effects of the TNFα observed with microinjection into the amygdala.
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Interactive effects of stress, CRF, and TNFα are arguably mediated by interaction of glia and
neurons (Adler et al., 2006; Rostène et al., 2007; Kawasaki et al. 2008; Wilkinson et al.
1993). In this regard, a likely source of cytokine input following stress is the activation of
glia (Bajetto et al., 2002), which when activated release cytokines including TNFα and IL1β
(Kreutzberg, 1996). They can be activated by neurotransmitters, by immune stimulation
through TLR4 receptors, or by a direct action of ethanol (Alfonso-Loeches et al., 2010;
Dolganiuc et al., 2006; Rostène et al., 2007; Szabo et al., 2007). The present results show
that TNFα can alter neural function, consistent with previous publications (Zhu et al., 2010).
Thus, glial activation by stress or ethanol may release cytokines that alter neural activity at
brain sites involved in anxiety-like behavior. The data showing that repeated stress or
repeated cytokine microinjection into the CeA can sensitize animals to anxiety-like behavior
induced by a subsequent ethanol withdrawal episode are consistent with just such a glial-
neuronal interaction. This interaction is supported by data showing that CRF and cytokines,
which can act both on neurons and glia (e.g., Jung et al., 2008; Wang et al., 2003; Gallagher
et al., 2008), can substitute for stress (Breese et al., 2004; 2008; Huang et al., 2010) and that
a CRF-1 antagonist blocks the action of both cytokines and CRF (Breese et al., 2004; Huang
et al., 2010; Wang et al., 2003, data herein). A requirement for such a glial-neural
interaction, as the basis of the sensitization by stress, CRF, and cytokines on withdrawal-
induced anxiety-like behavior, is that the cytokines are active at a brain site involved in
anxiety-like behavior. The illustration of altered neuronal activity in the CeA is direct
evidence for an action of cytokines at a relevant brain site. Whether CRF is the primary
controller within this site for this interactive CRF-cytokine process is unknown.
Nonetheless, because glia are a part of the innate immune system in the CNS and repeated
activation of glia by stress, immune challenge, CRF, or ethanol stimulation may “prime”
them for production of cytokines (Anisman et al., 2003; Frank et al., 2010; Hains et al.,
2010; Johnson et al., 2004), perhaps primed glia are responsible for some long-term neural
consequences (Figure 8). Finally, while alcoholism is a complex chronic disorder and no
single mechanism can explain uncontrolled drinking and associated consequences, the
results herein support the idea that CRF and cytokines (and hence neurons and glia) interact
to influence neuronal function, and thus may impact the role of stress in negative affect seen
in the alcoholic.
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Protocols for the experiments described herein.
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TNFα levels in brain 4.5 hours after termination of 1 hour of restraint stress. *p<0.05 versus
No Stress.
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Intra-amygdala injections of TNFα (10 ng) sensitize ethanol withdrawal anxiety in the rat.
Veh = artificial cerebrospinal fluid. *p<0.05 vs Control Diet/Veh; +<0.05 vs Ethanol Diet/
TNFα. CD = control diet; ED = ethanol diet.
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Intra-amygdala TNFα (100 ng in 0.5 ul) fails to increase plasma corticosterone. Non-
stressed rats were injected with vehicle (aCSF) or TNFα 45 min prior to blood sampling.
Stressed rats were injected with vehicle 30 minutes prior to 30 min restraint, then their blood
sampled 30 minutes after cessation of stress. *p<0.05 versus other groups.
Knapp et al. Page 18














A CRF-1R antagonist blocks the sensitizing effect of cytokines (MCP-1 or TNFα; 100 ng
ICV) on ethanol withdrawal anxiety. Rats were administered SSR125543 prior to either
cytokine during each of the first two of three ethanol withdrawal periods. Behavior was
recorded during the third withdrawal. CD = control diet; ED = ethanol diet, *p<0.05 vs CD/
Veh; +<0.05 vs ED-TNFα or ED-MCP-1.
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ICV administration of the MEK inhibitor SL327 blocks anxiety-like behavior induced by a
stress-sensitized ethanol withdrawal protocol in rats. *p < 0.05 Compared to other
treatments. ED = ethanol diet; CD = control diet, Vehicle = artificial cerebrospinal fluid.
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Physiological responses of amygdala neurons to TNFα. Representative neuronal firing rates
in a neuron from an amygdala slice preparation before, during and after TNFα (1.25 nM)
exposure (upper left panel). The firing rate increase relative to the average of the pre and
post-TNFα periods was significantly greater than rates obtained from non-TNFα exposed
cells. A similar comparison of the effect of TNFα (1.25 nM) on GABA release in the
amygdala slice is shown in the lower right panel lower right panel). Representative traces of
mIPSCs are shown before, during, and after TFNα in the upper right panel. Numbers in
parentheses are number of cells. mIPSCs = mini inhibitory post-synaptic currents. *p < 0.05
versus control.
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Table 1









      Experiment 2
CD Veh (10)** -- 131± 6 242 ± 5
CD TNFα (10) -- 129 ± 7 246 ± 6
ED TNFα (9) 10.2 ± 0.2 59 ± 6* 247 ± 6
ED Veh (9) 10.2 ± 0.3 58 ± 10* 239 ± 4
t(16)+ = NS *** F(1,34)= 97.1, p<0.0001 *** F(1,34)=NS
*p<0.05 vs either CD group
      Experiment 4
CD Veh (8) -- 165 281 ± 4
CD TNFα (8) -- 160 293 ± 4
ED Veh (8) 7.6 ± 0.5 129 267 ± 8
ED Veh TNFα (8) 8.0 ± 0.2 159 292 ± 7
ED Veh MCP-1 (8) 7.6 ± 0.3 140 305 ± 7*
ED SSR TNFα (8) 7.9 ± 0.3 136 274 ± 9
ED SSR MCP-1 (10) 7.9 ± 0.2 150 281 ± 9
F(4,38) = NS F(6,52) = NS F(6,52)= 2.93 (p<0.05)
* Significantly different from CD Veh control (p <0.05)
      Experiment 5
CD Veh No Stress (7) -- 107 ± 13 318 ± 7
CD SL327 No Stress (7) -- 104 ± 11 310 ± 8
ED Vehicle Stress (7) 7.5 ± 0.1 78 ± 8 318 ± 11
ED SL327 Stress (7) 7.7 ± 0.4 78 ± 8 315 ± 7
t(12)=NS ***F(1,24)=7.47, p<0.05 ***F(1,24)=NS
NS = non-significant ANOVA or t-test,
**
numbers in parentheses are n sizes per group;
+
numbers in parentheses are degrees of freedom.
CD = control diet; ED = ethanol diet;
***
main effect of ED exposed groups.
NS = not significant
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